Neurocrine Biosciences, Inc.
NBIX NASDAQHealthcare ★★★★★Latest Earnings Below forecast↓
Date
Jul 30, 2026
ET
EPS Est.
1.65
EPS Actual
1.39
Revenue Est.
$891.2M
Revenue Actual
$959M
Next Earnings Report
Date
Oct 27, 2026 · Tue
Time
After-market
Fiscal Period
FY2026 Q3
EPS Est.
2.59
Revenue Est.
$1.04B
Company Overview
Neurocrine Biosciences, Inc. (ticker NBIX) is listed on NASDAQ with a market cap of about $15.34B. Its next earnings report (FY2026 Q3) is expected on Oct 27, 2026 (ET), After-market, with consensus EPS of 2.59. In the last 15 reported quarters, EPS beat consensus estimates 6 times.
Actual EPS TrendRecently15Term · Feb 6, 2023 → Jul 30, 2026
Feb 6, 2023Range: -0.79 ~ 2.04Jul 30, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 30, 2026 | -- | 1.65 | Below forecast↓1.39 | $891.2M | $959M |
| May 5, 2026 | -- | 1.22 | Above forecast↑1.94 | $768.3M | $814.5M |
| Feb 11, 2026 | -- | 1.80 | 1.88 | $790.5M | $805.5M |
| Oct 28, 2025 | -- | 1.58 | Above forecast↑2.04 | $806.8M | $794.9M |
| Jul 30, 2025 | -- | 0.98 | 1.06 | $746.4M | $687.5M |
| May 5, 2025 | -- | 0.54 | Below forecast↓0.08 | $559.6M | $572.6M |
| Feb 6, 2025 | -- | 1.62 | Below forecast↓1.00 | $629.4M | $627.7M |
| Oct 30, 2024 | -- | 1.51 | Below forecast↓1.24 | $600.6M | $622.1M |
| Aug 1, 2024 | -- | 1.05 | Below forecast↓0.63 | $545.9M | $590.2M |
| May 1, 2024 | -- | 1.01 | Below forecast↓0.42 | $512.4M | $515.3M |
| Feb 7, 2024 | -- | 1.15 | Above forecast↑1.44 | $519.1M | $515.2M |
| Oct 31, 2023 | -- | 0.97 | Below forecast↓0.82 | $468.2M | $498.8M |
| Aug 1, 2023 | -- | 0.78 | Above forecast↑0.95 | $447.3M | $452.7M |
| May 3, 2023 | -- | 0.26 | Below forecast↓-0.79 | $409.3M | $420.4M |
| Feb 6, 2023 | -- | 1.16 | Below forecast↓0.88 | $408.9M | $412M |
Original Filings (SEC)
10-Q2026-07-31 ↗
8-K2026-07-30 ↗
8-K2026-05-28 ↗
8-K2026-05-18 ↗
10-Q2026-05-05 ↗
8-K2026-05-05 ↗
8-K2026-04-06 ↗
10-K2026-02-11 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
